Periperal Blood Lymphocytes During Prostate RT

A Pilot Study of Gamma H2AX DNA Repair Foci Kinetics in Peripheral Blood Lymphocytes During Prostate Cancer Radiotherapy

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01899391

Enrollment

Registered

2013-07-15

Start date

2009-08-31

Completion date

2013-03-31

Last updated

2013-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Prostate cancer

Brief summary

Right now it is not possible to predict which patients are going to react more to RT. Many things could affect patient's response to radiation. One of the factors is whether the person can repair damage to the genetic material (DNA/RNA) caused by the RT. There is some evidence that a certain protein called Gamma H2AX is involved in DNA damage and repair and this can be used to predict the sensitivity of individual patients. The investigators will be studying this protein: Gamma H2AX) in the blood samples of prostate cancer patients exposed to both computed tomography (CT) scan and RT treatment. This will help us to understand why different individuals show differences in side effects following RT.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Intermediate-risk prostate cancer patients (T1/T2N0M0 with either GS \< 7 and PSA between 10-20 ng/ml or GS 7 and PSA less than 20 ng/ml). * Planned for radical RT to the prostate with IMRT planning (79Gy/39fractions or 60 Gy/20 fractions). * No contraindications to diagnostic CT scanning. * Prostate volumes will be less than 80 cc to control the planning dose volume histogram (DVH) as much as possible in terms of rectal and bladder volumes. * No known DNA repair disorders (e.g. family history of AT, BRCA1/2 or Li Fraumeni syndrome) or contraindications to radical pelvic RT.

Exclusion criteria

* Inability to provide informed consent. * Patient having contraindications to diagnostic CT scan. * Patients who have unobtainable data regarding previous therapy and their clinical outcome. * Patients should not have any diagnostic X-rays or CAT scans 2 weeks prior to their enrollment into the study.

Design outcomes

Primary

Measure	Time frame
Gamma H2AX in peripheral blood lymphocytes.	1 year

Secondary

Measure	Time frame
Gamma H2AX during RT	1 year
Gamma H2AX following RT planning (CT scan).	1 year

Outcome results